UNSPSC 51343508: Tenofovir alafenamide

This classification denotes a reverse transcriptase inhibitor and purine antagonist C21H29N6O5P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EL9943AG5J, chemically known as l-alanine, n-((s)-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester, but more generally known as tenofovir alafenamide, which bears US NIH Compound Identifier 9574768. Most nations, for tariff and trade purposes, schedule tenofovir alafenamide under HS 29335995 and SITC 51576.

As of Q4 2014, TENOFOVIR ALAFENAMIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CN1CNC2C1NCNC2N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3CCCCC3.

UNSPSC 51343508 Tenofovir alafenamide is a Commodity code for a specific antiretroviral pharmaceutical product, but recent state and local solicitations tagged under this code do not reflect procurement of tenofovir alafenamide itself. Instead, the opportunities on record show state and local health agencies acquiring other pharmaceutical products — antibiotics, opioid-reversal agents, and drug deactivation systems — through piggyback contracts and competitive bidding processes. The actual buying pattern under this code appears misaligned with the nominal commodity name, suggesting either data-tagging variance or that jurisdictions are using the code to flag pharmaceutical procurement more broadly.

Activity is sparse and geographically limited. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline hyclate and ciprofloxacin hydrochloride with a total contract value of $2,999,999.11 over three years; this was a completed award through an Invitation for Bid process, not an open solicitation. Seminole County, Florida released an IFB in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a two-year initial term plus one-year renewal option. Both opportunities required compliance with drug-free workplace certification and federal employment verification. No set-aside or preference programs were identified in either record.